MedTrace Logo

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

NCT03422679 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2024-01-16

Study results available
· View outcomes & findings →

Summary

This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.

Conditions

Interventions

DRUG

CB-103

Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.

Sponsors & Collaborators

  • Cellestia Biotech AG

    lead INDUSTRY

Principal Investigators

  • Elena Garalda, MD, PhD · Vall d'Hebron University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-05
Primary Completion
2022-11-11
Completion
2022-11-11
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • South Korea
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03422679 on ClinicalTrials.gov